{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T20:02:40Z","timestamp":1790020960835,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005525","name":"Society of Toxicology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005525","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020869","name":"AstraZeneca KK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jiac.2025.102840","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:57:35Z","timestamp":1761184655000},"page":"102840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The continued impact of COVID-19 during the Omicron era on immunocompromised individuals in Japan"],"prefix":"10.1016","volume":"31","author":[{"given":"Toshibumi","family":"Taniguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Hoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Homma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kanazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Tateda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102840_bib2","year":"2020","journal-title":"COVID-19 pandemic"},{"key":"10.1016\/j.jiac.2025.102840_bib4","unstructured":"Ministry of Health, Labour and Welfare. Special measures concerning novel coronavirus infection. https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000188411_00048.html; 2024. [Accessed 17 April 2025]. (In Japanese)."},{"key":"10.1016\/j.jiac.2025.102840_bib5","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3390\/medicina59020202","article-title":"COVID-19 mRNA vaccine effectiveness against elderly frail people","volume":"59","author":"Kountouras","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jiac.2025.102840_bib6","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2665-9913(21)00247-2","article-title":"COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses","volume":"3","author":"Fagni","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.jiac.2025.102840_bib7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamaoncol.2021.5771","article-title":"Association of COVID-19 vaccination with SARS-CoV-2 infection in patients with cancer: a US nationwide Veterans Affairs study","volume":"8","author":"Wu","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jiac.2025.102840_bib8","first-page":"881","article-title":"COVID-19 disease burden in immunocompromised patients","volume":"44","author":"Kuroishi","year":"2023","journal-title":"Ther Res"},{"key":"10.1016\/j.jiac.2025.102840_bib9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s12325-024-03043-0","article-title":"Is COVID-19 still a threat? An expert opinion review on the continued healthcare burden in immunocompromised individuals","volume":"42","author":"Spinner","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.jiac.2025.102840_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33425\/2641-4317.1145","article-title":"Impact of coronavirus pandemic on immunocompromised patients- a detailed review","volume":"5","author":"Vijayan","year":"2022","journal-title":"Int J Psychiatr Res"},{"key":"10.1016\/j.jiac.2025.102840_bib11","article-title":"Emotional analysis of tweets about clinically extremely vulnerable COVID-19 groups","volume":"14","author":"Awoyemi","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.jiac.2025.102840_bib12","unstructured":"Japan Institute for Health Security (JIHS). Proposed guidelines for clinical response to COVID-19 in immunocompromised individuals. https:\/\/id-info.jihs.go.jp\/surveillance\/iasr\/12889-covid19-87.html; 2024. [Accessed 21 May 2025]. (In Japanese)."},{"key":"10.1016\/j.jiac.2025.102840_bib13","article-title":"Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study","volume":"35","author":"Evans","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jiac.2025.102840_bib14","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s12325-023-02754-0","article-title":"Assessing the burden and cost of COVID-19 across variants in commercially insured immunocompromised populations in the United States: updated results and trends from the ongoing EPOCH-US study","volume":"41","author":"Ketkar","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.jiac.2025.102840_bib15","article-title":"Risk of severe COVID-19 outcomes after autumn 2022 COVID-19 booster vaccinations: a pooled analysis of national prospective cohort studies involving 7.4 million adults in England, Northern Ireland, Scotland and Wales","volume":"37","author":"Bedston","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jiac.2025.102840_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2025.106432","article-title":"Immunocompromised individuals remain at risk of COVID-19: 2023 results from the observational INFORM study","volume":"90","author":"Quint","year":"2025","journal-title":"J Infect"},{"key":"10.1016\/j.jiac.2025.102840_bib17","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ajt.2024.03.016","article-title":"Excess mortality in COVID-19-affected solid organ transplant recipients across the pandemic","volume":"24","author":"Yamanaga","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jiac.2025.102840_bib18","unstructured":"Japan Institute for Health Security (JIHS). Second report on the BA.2.86 lineage of the novel coronavirus (SARS-CoV-2). https:\/\/id-info.jihs.go.jp\/diseases\/sa\/covid-19\/130\/sars-cov-2-ba-2-86-2.html; 2023. [Accessed 2 July 2025]. (In Japanese)."},{"key":"10.1016\/j.jiac.2025.102840_bib19","unstructured":"Japan Institute for Health Security (JIHS). Overview of SARS-CoV-2 variants (previous data). https:\/\/id-info.jihs.go.jp\/diseases\/sa\/covid-19\/190\/flu2-1-2.html; 2025. [Accessed 12 May 2025]. (In Japanese)."},{"key":"10.1016\/j.jiac.2025.102840_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2024.07.007","article-title":"Clinical characteristics and COVID-19 related outcomes of immunocompromised patients receiving tixagevimab\/cilgavimab pre-exposure prophylaxis in Japan","volume":"31","author":"Taniguchi","year":"2025","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102840_bib21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jiac.2021.10.021","article-title":"Clinical characteristics and prognosis of immunosuppressed inpatients with COVID-19 in Japan","volume":"28","author":"Nomoto","year":"2022","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102840_bib22","unstructured":"[By prefecture] trends in COVID-19 vaccination rates https:\/\/web.sapmed.ac.jp\/canmol\/coronavirus\/japan_vaccine.html?a=1&age=65&d=2&avg. [Accessed 17 April 2025]. (In Japanese)."},{"key":"10.1016\/j.jiac.2025.102840_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20344","article-title":"How do immunocompromised people experience the changes in their working lives during the COVID-19 pandemic? Results from a mixed-methods study in Germany","volume":"9","author":"Wegener","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.jiac.2025.102840_bib24","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1182\/bloodadvances.2021006302","article-title":"CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma","volume":"6","author":"Okamoto","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jiac.2025.102840_bib25","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jiac.2025.102840_bib26","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.2021012443","article-title":"Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies","volume":"138","author":"Ghione","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jiac.2025.102840_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102553","article-title":"Decoding the historical tale: COVID-19 impact on haematological malignancy patients\u2014EPICOVIDEHA insights from 2020 to 2022","volume":"71","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jiac.2025.102840_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002266","article-title":"Severity of COVID-19 in patients with lung cancer: evidence and challenges","volume":"9","author":"Passaro","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jiac.2025.102840_bib30","unstructured":"Otsuka S., Hiraoka K., Iwashiro N. Impact of nosocomial infection of COVID-19 on patients with lung cancer\/malignant pleural mesothelioma in our institution. Journal of the Medical Assoc of South Hokkaido 2024;7:107\u201311. https:\/\/www.jstage.jst.go.jp\/article\/dij\/7\/1\/7_153\/_pdf\/-char\/en. (In Japanese)."},{"key":"10.1016\/j.jiac.2025.102840_bib31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12879-024-09131-4","article-title":"Evaluation of characteristics and prognosis of COVID-19 patients requiring invasive mechanical ventilation during dominance of nonvariant, alpha, delta, and omicron variants in tertiary hospitals of Japan","volume":"24","author":"Sakuramoto","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2025.102840_bib32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1186\/s12879-024-09633-1","article-title":"Clinical and virological features of SARS-CoV-2 Omicron variant-infected immunocompromised patients receiving immunosuppressive medications","volume":"24","author":"Nakamura","year":"2024","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2025.102840_bib33","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/vaccines12060634","article-title":"Retrospective, observational analysis on the impact of SARS-CoV-2 variant Omicron in hospitalized immunocompromised patients in a German hospital network\u2014the VISAGE study","volume":"12","author":"Nachtigall","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jiac.2025.102840_bib34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.35772\/ghm.2023.01053","article-title":"A novel protocol for de-isolating moderately and severely immunocompromised COVID-19 patients","volume":"5","author":"Kamegai","year":"2023","journal-title":"Glob Health Med"},{"key":"10.1016\/j.jiac.2025.102840_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.jiac.2025.102631","article-title":"Duration of infectious virus shedding of SARS-CoV-2 Omicron variant among immunocompromised patients","volume":"31","author":"Kamegai","year":"2025","journal-title":"J Infect Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T10:06:31Z","timestamp":1773828391000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1341321X25002375"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102840","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The continued impact of COVID-19 during the Omicron era on immunocompromised individuals in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102840"}}